COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS AFFECTED BY CHRONIC KIDNEY DISEASE IN ITALY

被引：0
|
作者：
Di Costanzo, A. [1 ]
Uster, A. [2 ]
Vassallo, C. [1 ]
Fiorentino, F. [1 ]
机构：
[1] IQVIA Solut Srl, Milan, Italy
[2] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE117
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of epoetin alfa in patients on chronic kidney dialysis
    Hollenbeak, Christopher
    Davies, Andrew
    McClellan, William M.
    de Lissovoy, Gregory
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (04) : A45 - A45
  • [22] COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR PATIENTS WITH CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS (CKD AP) UNDERGOING HAEMODIALYSIS IN ITALY
    Cicchetti, A.
    Manenti, L.
    Mennini, F. S.
    Aiello, A.
    Mariano, E.
    Prada, M.
    Soro, M.
    VALUE IN HEALTH, 2023, 26 (12) : S163 - S163
  • [23] COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN THE TREATMENT OF T2D WITH PREVIOUS CARDIOVASCULAR DISEASE IN ITALY
    Iannazzo, S.
    Mannucci, E.
    Reifsnider, O.
    Maggioni, A. P.
    VALUE IN HEALTH, 2017, 20 (09) : A480 - A480
  • [24] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Ramos, Mafalda
    Men, Peng
    Wang, Xu
    Ustyugova, Anastasia
    Lamotte, Mark
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [25] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Mafalda Ramos
    Peng Men
    Xu Wang
    Anastasia Ustyugova
    Mark Lamotte
    Cost Effectiveness and Resource Allocation, 19
  • [26] Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
    Erickson, Kevin F.
    Japa, Sohan
    Owens, Douglas K.
    Chertow, Glenn M.
    Garber, Alan M.
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (12) : 1250 - 1258
  • [27] Cost-effectiveness of chronic kidney disease mass screening test in Japan
    Kondo, Masahide
    Yamagata, Kunihiro
    Hoshi, Shu-Ling
    Saito, Chie
    Asahi, Koichi
    Moriyama, Toshiki
    Tsuruya, Kazuhiko
    Yoshida, Hideaki
    Iseki, Kunitoshi
    Watanabe, Tsuyoshi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2012, 16 (02) : 279 - 291
  • [28] Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease
    Tisdale, Rebecca L.
    Cusick, Marika M.
    Aluri, Kelly Zhang
    Handley, Thomas J.
    Joyner, Alice Kate Cummings
    Salomon, Joshua A.
    Chertow, Glenn M.
    Goldhaber-Fiebert, Jeremy D.
    Owens, Douglas K.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2022, 37 (13) : 3380 - 3387
  • [29] Cost-effectiveness of chronic kidney disease mass screening test in Japan
    Masahide Kondo
    Kunihiro Yamagata
    Shu-Ling Hoshi
    Chie Saito
    Koichi Asahi
    Toshiki Moriyama
    Kazuhiko Tsuruya
    Hideaki Yoshida
    Kunitoshi Iseki
    Tsuyoshi Watanabe
    Clinical and Experimental Nephrology, 2012, 16 : 279 - 291
  • [30] Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia
    Lim, Soo Kun
    Lee, Shaun Wen Huey
    PLOS ONE, 2024, 19 (03):
12345